Expression of Shiga toxin 2e glycosphingolipid receptors of primary porcine brain endothelial cells and toxin-mediated breakdown of the blood-brain barrier

Glycobiology

Volumn 23, Issue 6, 2013, Pages 745-759

  Meisen, Iris ^a,b   Rosenbrück, Regina ^a   Galla, Hans Joachim ^c   Hüwel, Sabine ^c   Kouzel, Ivan U ^a   Mormann, Michael ^a   Karch, Helge ^a   Müthing, Johannes ^a,b  

^a Department Hygiene and Medical Microbiology   (Germany)

^b Interdisciplinary Center for Clinical Research (IZKF)   (Germany)

^c UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

edema disease; glycolipids; lipid rafts; mass spectrometry; TLC immunostaining

Indexed keywords

CERAMIDE; GLOBOTETRAOSYLCERAMIDE; GLOBOTRIAOSYLCERAMIDE; GLYCOSPHINGOLIPID; LONG CHAIN FATTY ACID; SHIGA TOXIN; SPHINGANINE; TOTO; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CELL HETEROGENEITY; CONTROLLED STUDY; CYTOTOXICITY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; HYDROXYLATION; IN VITRO STUDY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL;

EDEMA DISEASE; GLYCOLIPIDS; LIPID RAFTS; MASS SPECTROMETRY; TLC IMMUNOSTAINING;

ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CARBOHYDRATE CONFORMATION; CARBOHYDRATE SEQUENCE; CELL CULTURE TECHNIQUES; CELL MEMBRANE; CELLS, CULTURED; ELECTRIC IMPEDANCE; ENDOTHELIAL CELLS; ENDOTHELIUM; GLOBOSIDES; GLYCOLIPIDS; MOLECULAR SEQUENCE DATA; PRIMARY CELL CULTURE; RECEPTORS, CELL SURFACE; SHIGA TOXIN 2; SUS SCROFA; TRIHEXOSYLCERAMIDES;

EID: 84877299906     PISSN: 09596658     EISSN: 14602423     Source Type: Journal    
DOI: 10.1093/glycob/cwt013     Document Type: Article

References (95)

1. Bauwens A, Betz J, Meisen I, Kemper B, Karch H, Müthing J. 2013. Facing glycosphingolipid-Shiga toxin interaction: Dire straits for endothelial cells of the human vasculature. Cell Mol Life Sci. 70:425-457.
2. Bauwens A, Bielaszewska M, Kemper B, Langehanenberg P, von Bally G, Reichelt R, Mulac D, Humpf HU, Friedrich AW, Kim KS, et al. 2011. Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. Thromb Haemost. 105:515-528.
3. Beddoe T, Paton AW, Le Nours J, Rossjohn J, Paton JC. 2010. Structure, biological functions and applications of the AB5 toxins. Trends Biochem Sci. 35:411-418.
4. Bergan J, Dyve Lingelem AB, Simm R, Skotland T, Sandvig K. 2012. Shiga toxins. Toxicon. 60:1085-1107.
5. Bethke U, Kniep B, Mühlradt PF. 1987. Forssman glycolipid, an antigenic marker for a major subpopulation of macrophages from murine spleen and peripheral lymph nodes. J Immunol. 138:4329-4335.
6. Bethke U, Müthing J, Schauder B, Conradt P, Mühlradt PF. 1986. An improved semi-quantitative enzyme immunostaining procedure for glycosphingolipid antigens on high performance thin layer chromatograms. J Immunol Methods. 89:111-116.
7. Betz J, Bauwens A, Kunsmann L, Bielaszewska M, Mormann M, Humpf HU, Karch H, Friedrich AW, Müthing J. 2012. Uncommon membrane distribution of Shiga toxin glycosphingolipid receptors in toxin-sensitive human glomerular microvascular endothelial cells. Biol Chem. 393:133-147.
8. Betz J, Bielaszewska M, Thies A, Humpf HU, Dreisewerd K, Karch H, Kim KS, Friedrich AW, Müthing J. 2011. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: Differential association with membrane lipid raft microdomains. J Lipid Res. 52:618-634.
9. Bielaszewska M, Karch H. 2005. Consequences of enterohaemorrhagic Escherichia coli infection for the vascular endothelium. Thromb Haemost. 94:312-318.
10. Bielaszewska M, Mellmann A, Zhang W, Köck R, Fruth A, Bauwens A, Peters G, Karch H. 2011. Characterisation of the Escherichia coli strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. Lancet Infect Dis. 11:671-676.
11. Bosworth BT, Samuel JE, Moon HW, O'Brien AD, Gordon VM, Whipp SC. 1996. Vaccination with genetically modified Shiga-like toxin IIe prevents edema disease in swine. Infect Immun. 64:55-60.
12. Bouhours D, Pourcel C, Bouhours JF. 1996. Simultaneous expression by porcine aorta endothelial cells of glycosphingolipids bearing the major epitope for human xenoreactive antibodies (Galα1-3Gal), blood group H determinant and N-glycolylneuraminic acid. Glycoconj J. 13:947-953.
13. Boyd B, Tyrrell G, Maloney M, Gyles C, Brunton J, Lingwood C. 1993. Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targetting and results in verotoxin 1-like disease in pigs. J Exp Med. 177:1745-1753.
14. Brown DA, Rose KJ. 1992. Sorting of GPI-anchored proteins to glycolipid enriched membrane subdomains during transport to the apical cell surface. Cell. 68:533-544.
15. Chester MA. 1999. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids. Recommendations 1997. Glycoconj J. 16:1-6.
16. DeGrandis S, Law H, Brunton J, Gyles C, Lingwood CA. 1989. Globotetraosylceramide is recognized by the pig edema disease toxin. J Biol Chem. 264:12520-12525.
17. Distler U, Souady J, Hülsewig M, Drmi-Hofman I, Haier J, Friedrich AW, Karch H, Senninger N, Dreisewerd K, Berkenkamp S, et al. 2009. Shiga toxin receptor Gb3Cer/CD77: Tumor association and promising therapeutic target in pancreas and colon cancer. PLoS ONE. 4:e6813.
18. Dittmer JC, Lester RL. 1964. Simple specific spray for detection of phospholipids on thin-layer chromatograms. J Lipid Res. 5:126-127.
19. Domon B, Costello CE. 1988a. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. Glycoconj J. 5:397-440.
20. Domon B, Costello CE. 1988b. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. Biochemistry. 27:1534-1543.
21. Falguières T, Mallard F, Baron C, Hanau D, Lingwood C, Goud B, Salamero J, Johannes L. 2001. Targeting of Shiga toxin B-subunit to retrograde transport route in association with detergent-resistant membranes. Mol Biol Cell. 12:2453-2468.
22. Falguières T, Römer W, Amessou M, Afonso C, Wolf C, Tabet JC, Lamaze C, Johannes L. 2006. Functionally different pools of Shiga toxin receptor, globotriaosyl ceramide, in HeLa cells. FEBS J. 273:5205-5218.
23. Fantini J. 2003. How sphingolipids bind and shape proteins: Molecular basis of lipid-protein interactions in lipid shells, rafts and related biomembrane domains. Cell Mol Life Sci. 60:1027-1032.
24. Fantini J, Maresca M, Hammache D, Yahi N, Delézay O. 2000. Glycosphingolipid (GSL) microdomain as attachment platforms for host pathogens and their toxins on intestinal epithelial cells: Activation of signal transduction pathways and perturbations of intestinal absorption and secretion. Glycoconj J. 17:173-179.
25. Franke H, Galla HJ, Beuckmann CT. 1999. An improved low-permeability in vitro-model of the blood-brain barrier: Transport studies on retinoids, sucrose, haloperidol, caffeine and mannitol. Brain Res. 818:65-71.
26. Franke H, Galla HJ, Beuckmann CT. 2000. Primary cultures of brain microvessel endothelial cells: A valid and flexible model to study drug transport through the blood-brain barrier in vitro. Brain Res Protoc. 5:248-256.
27. Fratamico PM, Bagi LK, Bush EJ, Solow BT. 2004. Prevalence and characterization of Shiga toxin-producing Escherichia coli in swine feces recovered in the National Animal Health Monitoring System's Swine 2000 Study. Appl Environ Microbiol. 70:7173-7178.
28. Gupta G, Surolia A. 2010. Glycosphingolipids in microdomain formation and their spatial organization. FEBS Lett. 584:1634-1641.
29. Hoffmann P, Hülsewig M, Duvar S, Ziehr H, Mormann M, Peter-Katalini J, Friedrich AW, Karch H, Müthing J. 2010. On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nanoelectrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom. 24:2295-2304.
30. Hoheisel D, Nitz T, Franke H, Wegener J, Hakvoort A, Tilling T, Galla HJ. 1998. Hydrocortisone reinforces the blood-brain properties in a serum free cell culture system. Biochem Biophys Res Commun. 247:312-315.
31. Holst O, Zähringer U, Brade H, Zamojski A. 1991. Structural analysis of the heptose/hexose region of the lipopolysaccharide from Escherichia coli K-12 strain W3100. Carbohydr Res. 215:323-335.
32. Johannes L, Römer W. 2010. Shiga toxins-from cell biology to biomedical applications. Nat Rev Microbiol. 8:105-116.
33. Johansen M, Andresen LO, Jorsal SE, Thomsen LK, Waddell TE, Gyles CL. 1997. Prevention of edema disease in pigs by vaccination with verotoxin 2e toxoid. Can J Vet Res. 61:280-285.
34. Karch H, Tarr PI, Bielaszewska M. 2005. Enterohaemorrhagic Escherichia coli in human medicine. Int J Med Microbiol. 295:405-418.
35. Karmali MA, Gannon V, Sargeant JM. 2010. Verocytotoxin-producing Escherichia coli (VTEC). Vet Microbiol. 140:360-370.
36. Koma M, Miyagawa S, Honke K, Ikeda Y, Koyota S, Miyoshi S, Matsuda H, Tsuji S, Shirakura R, Taniguchi N. 2000. Reduction of the major xenoantigen on glycosphingolipids of swine endothelial cells by various glycosyltransferases. Glycobiology. 10:745-751.
37. Kovbasnjuk O, Edidin M, Donovitz M. 2001. Role of lipid rafts in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. J Cell Sci. 114:4025-4031.
38. Lencer WI, Saslowsky D. 2005. Raft trafficking of AB5 subunit bacterial toxins. Biochim Biophys Acta. 1746:314-321.
39. Leonardsson I, Miller-Podraza H, Teneberg S, Breimer ME. 2004. Isolation and partial characterization of Galα-containing polyglycosylceramides from porcine tissue. Xenotransplantation. 11:97-100.
40. Levery SB. 2005. Glycosphingolipid structural analysis and glycosphingolipidomics. Methods Enzymol. 405:300-369.
41. Li Y, Teneberg S, Thapa P, Bendelac A, Levery SB, Zhou D. 2008. Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry. Glycobiology. 18:158-165.
42. Li Y, Zhou D, Xia C, Wang PG, Levery SB. 2008. Sensitive quantitation of isoglobotriaosylceramide in the presence of isobaric components using electrospray ionization-ion trap mass spectrometry. Glycobiology. 18:166-176.
43. Lingwood CA. 1996. Role of verotoxin receptors in pathogenesis. Trends Microbiol. 4:147-153.
44. Lingwood CA, Binnington B, Manis A, Branch DR. 2010. Globotriaosyl ceramide receptor function-where membrane structure and pathology intersect. FEBS Lett. 584:1879-1886.
45. Lingwood D, Simons K. 2007. Detergent resistance as a tool in membrane research. Nat Protoc. 2:2159-2165.
46. Lochnit G, Geyer R, Heinz E, Rietschel ET, Zähringer U, Müthing J. 2001. Chemical biology and biomedicine: glycolipids and glycosphingolipids. In: Fraser-Reid BO, Tatsuta K, Thiem J, editors. Glycoscience: Chemistry and Chemical Biology, Vol. III. Heidelberg: Springer-Verlag. p. 2183-2249.
47. London E, Brown DA. 2000. Insolubility of lipids in Triton X-100: Physical origin and relationship to sphingolipid/cholesterol membrane domains (rafts). Biochim Biophys Acta. 1508:182-195.
48. MacLeod DL, Gyles CL, Wilcock BP. 1991. Reproduction of edema disease of swine with purified Shiga-like toxin-II variant. Vet Pathol. 28:66-73.
49. Mainil J. 1999. Shiga/verocytotoxins and Shiga/verotoxigenic Escherichia coli in animals. Vet Res. 30:235-257.
50. Mainil JG, Daube G. 2005. Verotoxigenic Escherichia coli from animals, humans and foods: Who's who J Appl Microbiol. 98:1332-1344.
51. Matise I, Sirinarumitr T, Bosworth BT, Moon HW. 2000. Vascular ultrastructure and DNA fragmentation in swine infected with Shiga toxin-producing Escherichia coli. Vet Pathol. 37:318-327.
52. Matthes F, Wölte P, Böckenhoff A, Hüwel S, Schulz M, Hyden P, Fogh J, Gieselmann V, Galla HJ, Matzner U. 2011. Transport of arylsulfatase A across the blood-brain barrier in vitro. J Biol Chem. 286:17487-17494.
53. Meisen I, Friedrich AW, Karch H, Witting U, Peter-Katalini J, Müthing J. 2005. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high-and low-affinity binding ligands of Shiga toxin 1. Rapid Commun Mass Spectrom. 19:3659-3665.
54. Meisen I, Mormann M, Müthing J. 2011. Thin-layer chromatography, overlay technique and mass spectrometry: A versatile triad advancing glycosphingolipidomics. Biochim Biophys Acta. 1811:875-896.
55. Meisen I, Peter-Katalini J, Müthing J. 2004. Direct analysis of silica gel extracts from immunostained glycosphingolipids by nanoelectrospray ionization quadrupole time-of-flight mass spectrometry. Anal Chem. 76:2248-2255.
56. Mellmann A, Harmsen D, Cummings CA, Zentz EB, Leopold SR, Rico A, Prior K, Szczepanowski R, Ji Y, Zhang W, et al. 2011. Prospective genomic characterization of the German enterohemorrhagic Escherichia coli O104:H4 outbreak by rapid next generation sequencing technology. PLoS ONE. 6(7):e22751.
57. Melton-Celsa A, Mohawk K, Teel L, O'Brien A. 2012. Pathogenesis of Shiga-toxin producing Escherichia coli. Curr Top Microbiol Immunol. 357:67-103.
58. Merrill AH, Jr. 2011. Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev. 111:6387-6422.
59. Meuth SG, Göbel K, Kanyshkova T, Ehling P, Ritter MA, Schwindt W, Bielaszewska M, Lebiedz P, Coulon P, Herrmann AM, et al. 2012. Thalamic involvement in patients with neurologic impairment due to Shiga toxin-producing E. coli. Ann Neurol. doi:10.1002/ana.23814.
60. Moxley RA. 2000. Edema disease. Vet Clin North Am Food Anim Pract. 16:175-185.
61. Müller-Loennies S, Lindner B, Brade H. 2003. Structural analysis of oligosaccharides from lipopolysaccharide (LPS) of Escherichia coli K12 strain W3100 reveals a link between inner and outer core LPS biosynthesis. J Biol Chem. 278:34090-34101.
62. Müthing J. 1998. TLC in structure and recognition studies of glycosphingolipids. In: Hounsell EF, editor. Methods in Molecular Biology. Totawa, NJ: Humana Press Inc. p. 183-195.
63. Müthing J, Duvar S, Heitmann D, Hanisch FG, Neumann U, Lochnit G, Geyer R, Peter-Katalini J. 1999. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. Glycobiology. 9:459-468.
64. Müthing J, Meisen I, Zhang W, Bielaszewska M, Mormann M, Bauerfeind R, Schmidt MA, Friedrich AW, Karch H. 2012. Promiscuous Shiga toxin 2e and its intimate relationship to Forssman. Glycobiology. 22:849-862.
65. Müthing J, Schweppe CH, Karch H, Friedrich AW. 2009. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. Thromb Haemost. 101:252-264.
66. Müthing J, Spanbroek R, Peter-Katalini J, Hanisch FG, Hanski C, Hasegawa A, Unland F, Lehmann J, Tschesche H, Egge H. 1996. Isolation and structural characterization of fucosylated gangliosides with linear poly-N-acetyllactosaminyl chains from human granulocytes. Glycobiology. 6:147-156.
67. Oanh TKN, Nguyen VK, De Greve H, Goddeeris BM. 2012. Protection of piglets against edema disease by maternal immunization with Stx2e toxoid. Infect Immun. 80:469-473.
68. Obata F. 2010. Influence of Escherichia coli Shiga toxin on the mammalian central nervous system. Adv Appl Microbiol. 71:1-19.
69. Obrig TG. 2010. Escherichia coli Shiga toxin mechanisms of action in renal disease. Toxins. 2:2769-2794.
70. Obrig TG, Karpman D. 2012. Shiga toxin pathogenesis: Kidney complications and renal failure. Curr Top Microbiol Immunol. 357:105-136.
71. Okuda T, Nakakita SI, Nakayama KI. 2010. Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF-α stimulation. Glycoconj J. 27:287-296.
72. Prinetti A, Loberto N, Chigorno V, Sonnino S. 2009. Glycosphingolipid behaviour in complex membranes. Biochim Biophys Acta. 1788:184-193.
73. Römer W, Berland L, Chambon V, Gaus K, Windschiegl B, Tenza D, Aly MRE, Fraisier V, Florent JC, Perrais D, et al. 2007. Shiga toxin induces tubular membrane invaginations for its uptake into cells. Nature. 450:670-675.
74. Sandvig K, Bergan J, Dyve AB, Skotland T, Torgersen ML. 2010. Endocytosis and retrograde transport of Shiga toxin. Toxicon. 56:1181-1185.
75. Sandvig K, Garred O, Prydz K, Kozlov JV, Hansen SH, van Deurs B. 1992. Retrograde transport of endocytosed Shiga toxin to the endoplasmic reticulum. Nature. 358:510-512.
76. Scheutz F, Teel LD, Beutin L, Piérard D, Buvens G, Karch H, Mellmann A, Caprioli A, Tozzoli R, Morabito S, et al. 2012. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stxs nomenclature. J Clin Microbiol. 50:2951-2963.
77. Schweppe CH, Bielaszewska M, Pohlentz G, Friedrich AW, Büntemeyer H, Schmidt MA, Kim KS, Peter-Katalini J, Karch H, Müthing J. 2008. Glycosphingolipids in vascular endothelial cells: Relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. Glycoconj J. 25:291-304.
78. Schweppe CH, Hoffmann P, Nofer JR, Pohlentz G, Mormann M, Karch H, Friedrich AW, Müthing J. 2010. Neutral glycosphingolipids in human blood: A precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors. J Lipid Res. 51:2282-2294.
79. Sharon N. 2006. Carbohydrates as future anti-adhesion drugs for infectious diseases. Biochim Biophys Acta. 1760:527-537.
80. Sharon N, Ofek I. 2000. Safe as mother's milk: Carbohydrates as future antiadhesion drugs for bacterial diseases. Glycoconj J. 17:659-664.
81. Smith DC, Lord JM, Roberts LM, Johannes L. 2004. Glycosphingolipids as toxin receptors. Semin Cell Dev Biol. 15:397-408.
82. Smith DC, Sillence DJ, Falguières T, Jarvis RM, Johannes L, Lord JM, Platt FM, Roberts LM. 2006. The association of Shiga-like toxin with detergent-resistant membranes is modulated by glucosylceramide and is an essential requirement in the endoplasmic reticulum for a cytotoxic effect. Mol Biol Cell. 17:1375-1387.
83. Sonntag AK, Bielaszewska M, Mellmann A, Dierkens N, Schierack P, Wieler LH, Schmidt MA, Karch H. 2005. Shiga toxin 2e-producing Escherichia coli isolates from humans and pigs differ in their virulence profiles and interactions with intestinal epithelial cells. Appl Environ Microbiol. 71:8855-8863.
84. Souady J, Hülsewig M, Distler U, Haier J, Denz A, Pilarsky C, Senninger N, Dreisewerd K, Peter-Katalini J, Müthing J. 2011. Differences in CD75sand iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinomas and nontumoral liver tissues. Glycobiology. 21:584-594.
85. Souady J, Soltwisch J, Dreisewerd K, Haier J, Peter-Katalini J, Müthing J. 2009. Structural profiling of individual glycosphingolipids in a single thinlayer chromatogram by multiple sequential immunodetection matched with direct IR-MALDI-o-TOF mass spectrometry. Anal Chem. 81:9481-9492.
86. Spooner RA, Lord JM. 2012. How ricin and Shiga toxin reach the cytosol of target cells: Retrotranslocation from the endoplasmic reticulum. Curr Top Microbiol Immunol. 357:19-40.
87. Storck W, Meisen I, Gianmoena K, Pläger I, Kouzel IU, Bielaszewska M, Haier J, Mormann M, Humpf HU, Karch H, et al. 2012. Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation. Biol Chem. 393:785-799.
88. Tarr PI, Gordon CA, Chandler WL. 2005. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet. 365:1073-1086.
89. Thanabalasundaram G, Schneidewind J, Pieper C, Galla HJ. 2011. The impact of pericytes on the blood-brain barrier integrity depends critically on the pericyte differentiation stage. Int J Biochem Cell B. 43:1284-1293.
90. Valdivieso-Garcia A, MacLeod DL, Clarke RC, Gyles CL, Lingwood C, Boyd B, Durette A. 1996. Comparative cytotoxicity of purified Shiga-like toxin-IIe on porcine and bovine aortic endothelial and human colonic adenocarcinoma cells. J Med Microbiol. 45:331-337.
91. Vanhove B, Sébille F, Cassard A, Charreau B, Soulillou JP. 1998. Transcriptional and posttranscriptional regulation of α1,3- galactosyltransferase in activated endothelial cells results in decreased expression of Galα1,3Gal. Glycobiology. 8:481-487.
92. von Wedel-Parlow M, Wolte P, Galla HJ. 2009. Regulation of major efflux transporters under inflammatory conditions at the blood-brain barrier in vitro. J Neurochem. 111:111-118.
93. Waddell TE, Coomber BL, Gyles CL. 1998. Localization of potential binding sites for the edema disease verotoxin (VT2e) in pigs. Can J Vet Res. 62:81-86.
94. Warnier M, Römer W, Geelen J, Lesieur J, Amessou M, van den Heuvel L, Monnens L, Johannes L. 2006. Trafficking of Shiga toxin/Shiga-like toxin-1 in human glomerular microvascular endothelial cells and human mesangial cells. Kidney Int. 70:2085-2091.
95. Zoja C, Buelli S, Morigi M. 2010. Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. Pediatr Nephrol. 25:2231-2240.